MHRA Guidance on Decentralized Clinical Trials in the UK

Published on 22/12/2025

MHRA’s Guidance on Decentralized Clinical Trials in the UK

Decentralized clinical trials (DCTs), often referred to as virtual or remote trials, are transforming how clinical research is conducted globally. In the United Kingdom (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) has taken proactive steps to regulate and guide the use of DCTs, especially following the acceleration of digital adoption during the COVID-19 pandemic. Unlike traditional site-based models, DCTs allow participants to engage from their homes using telemedicine, electronic consent (eConsent), and remote monitoring technologies. While this approach improves access and convenience, it raises new regulatory challenges around data integrity, patient safety, and ethical oversight.

This article provides a detailed analysis of MHRA guidance on decentralized trials, highlighting the regulatory framework, key expectations for sponsors, and the practical challenges faced by NHS Trusts, CROs, and investigators in adopting this model.

Table of Contents

Background and Regulatory Framework

MHRA Position on DCTs

MHRA supports decentralized approaches as long as they comply with Good Clinical Practice (GCP) and ensure participant safety. Guidance documents, including MHRA’s Guidance on the Management of Clinical Trials During COVID-19, laid the groundwork for remote consent, telemedicine, and home delivery of investigational products. MHRA continues

to expand these principles into a long-term regulatory strategy.

HRA and Ethics Committees

The Health Research Authority (HRA) and Research Ethics Committees (RECs) review DCT protocols to ensure ethical compliance, transparency in digital processes, and patient comprehension of remote trial procedures.

Global Alignment

While independent, UK DCT guidance is harmonised with international initiatives such as the FDA DCT guidance, EMA reflection papers, and ICH E6(R3) principles on quality-by-design.

Core Insights on MHRA Guidance for Decentralized Trials

1. Informed Consent and eConsent

MHRA requires that electronic consent systems are validated, secure, and accessible to diverse populations. Participants must have the option for face-to-face discussions if preferred.

2. IMP Supply and Accountability

Home delivery of investigational medicinal products (IMPs) is permissible if robust chain-of-custody systems and temperature monitoring are in place. Documentation must be TMF-ready.

3. Remote Monitoring

Centralised and remote monitoring are encouraged, but sponsors must validate digital platforms and maintain strong CRO oversight to avoid data gaps.

4. Data Integrity and Security

MHRA highlights the need for validated systems, encrypted data transfer, and clear audit trails. Cybersecurity risks are subject to inspection review.

5. Patient Safety Monitoring

Telemedicine consultations must be supported by clear escalation pathways, and adverse events must be captured and reported in line with pharmacovigilance obligations.

6. NHS Infrastructure Readiness

NHS Trusts vary in digital maturity, creating implementation challenges. Sponsors must assess feasibility and provide support for site adoption of DCT models.

Best Practices for Decentralized Trials in the UK

Engage MHRA early when proposing DCT elements in trial protocols.
Validate digital tools for eConsent, data capture, and monitoring.
Train investigators and NHS staff in decentralized processes.
Include hybrid elements to support participants with limited digital literacy.
Document all DCT processes in the Trial Master File (TMF).

Scientific and Regulatory Evidence

MHRA Guidance on Clinical Trial Management During COVID-19
Medicines for Human Use (Clinical Trials) Regulations 2004
ICH E6(R2) and draft E6(R3) Good Clinical Practice
EMA Reflection Paper on Decentralized Elements
HRA Guidance on eConsent and Digital Trials

Special Considerations

Oncology Trials: Require hybrid models combining hospital visits for imaging with remote monitoring for routine follow-up.
Rare Diseases: DCTs offer improved access to geographically dispersed patient populations.
Pediatrics: Digital consent for parents and assent for children must be tailored and REC-approved.
Advanced Therapies (ATMPs): Complex administration often requires on-site visits, but follow-up can be decentralized.

When Sponsors Should Seek Regulatory Advice

When introducing fully decentralized trial designs.
If using novel digital health technologies for remote data collection.
For rare disease or pediatric populations with specific ethical considerations.
When integrating DCT data into global submissions with divergent regulatory expectations.

FAQs

1. Does MHRA allow fully decentralized trials?

Yes, provided patient safety, data integrity, and GCP compliance are maintained. Hybrid models are often preferred for feasibility.

2. How does MHRA regulate eConsent?

Systems must be validated, secure, and ensure participant understanding, with alternatives for those less digitally literate.

3. Can IMPs be delivered to patients at home?

Yes, if robust accountability systems and temperature monitoring are in place, documented for MHRA inspection.

4. What are the main inspection findings in UK DCTs?

Common issues include poor validation of digital systems, incomplete audit trails, and weak CRO oversight.

5. How do NHS Trusts adapt to DCTs?

Adoption varies. Digital maturity, staff training, and IT support determine readiness for decentralized models.

6. Do decentralized trials change pharmacovigilance obligations?

No. Sponsors must still capture and report adverse events promptly, even when monitoring is remote.

7. How does Brexit affect UK DCT regulation?

UK guidance is now independent but harmonised with EMA and ICH standards to ensure global acceptability of UK trial data.

Conclusion

Decentralized clinical trials in the UK reflect a broader shift toward patient-centric research and digital innovation. MHRA guidance encourages adoption while reinforcing GCP, data integrity, and patient safety. Sponsors, CROs, and NHS Trusts must carefully plan, validate, and document DCT elements to remain inspection-ready. By balancing flexibility with regulatory compliance, decentralized trials can expand access, reduce participant burden, and strengthen the UK’s role in global clinical research.